Bluebird Bio Inc. (NASDAQ:BLUE) traded down 3.7% on Wednesday . The company traded as low as $55.32 and last traded at $55.43, with a volume of 645,546 shares. The stock had previously closed at $57.54.

A number of research firms recently commented on BLUE. Zacks Investment Research lowered shares of Bluebird Bio from a “hold” rating to a “sell” rating in a report on Monday, May 2nd. Cantor Fitzgerald began coverage on shares of Bluebird Bio in a report on Thursday, June 2nd. They set a “hold” rating and a $42.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $117.00 price target on shares of Bluebird Bio in a report on Thursday, May 5th. Piper Jaffray Cos. reiterated a “buy” rating and set a $117.00 price target on shares of Bluebird Bio in a report on Wednesday, May 11th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Bluebird Bio in a report on Thursday, May 5th. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $94.84.

The company’s 50 day moving average is $51.30 and its 200 day moving average is $46.68. The stock’s market cap is $2.06 billion.

Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.15. The business earned $1.55 million during the quarter, compared to the consensus estimate of $2.01 million. During the same quarter in the prior year, the company earned ($1.57) earnings per share. Bluebird Bio’s quarterly revenue was down 68.6% compared to the same quarter last year. On average, analysts predict that Bluebird Bio Inc. will post ($6.14) earnings per share for the current fiscal year.

In other Bluebird Bio news, insider Eric Sullivan sold 2,912 shares of the stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $55.01, for a total value of $160,189.12. Following the sale, the insider now owns 4,456 shares of the company’s stock, valued at approximately $245,124.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Philip D. Gregory sold 2,931 shares of the stock in a transaction dated Thursday, June 16th. The shares were sold at an average price of $39.52, for a total value of $115,833.12. Following the completion of the sale, the insider now directly owns 30,069 shares in the company, valued at approximately $1,188,326.88. The disclosure for this sale can be found here.

Other large investors recently bought and sold shares of the company. RS Investment Management Co. LLC raised its stake in Bluebird Bio by 91.6% in the fourth quarter. RS Investment Management Co. LLC now owns 515,846 shares of the company’s stock worth $33,128,000 after buying an additional 246,622 shares in the last quarter. State of Tennessee Treasury Department raised its stake in Bluebird Bio by 45.4% in the fourth quarter. State of Tennessee Treasury Department now owns 191,963 shares of the company’s stock worth $12,328,000 after buying an additional 59,952 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Bluebird Bio by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 74,831 shares of the company’s stock worth $4,806,000 after buying an additional 4,454 shares in the last quarter. Jennison Associates LLC raised its stake in Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock worth $55,506,000 after buying an additional 545,727 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in Bluebird Bio by 53.4% in the fourth quarter. Wells Fargo & Company MN now owns 474,832 shares of the company’s stock worth $30,492,000 after buying an additional 165,303 shares in the last quarter.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.